Search Results

Patient-centered tracking of 340B policy in Washington: active bills, committee assignments, fact sheets Washington 340B Watch Stay informed on state-level actions, proposed legislation, and advocacy efforts View PDF CANN Public Comment: Washington HB 2145 — 340B Program Publication Date: 2/4/26 Comment opposing View PDF CANN Public Comment: Washington SB 5981 — 340B (Health Committee) Publication Date: 1/13/26 View PDF Current Legislative Session Activity in Washington Jan 16, 2026 | SB 5981 Scheduled for public

Patient-centered tracking of 340B policy in Washington DC: active bills, committee assignments, fact Washington, DC 340B Watch Stay informed on state-level actions, proposed legislation, and advocacy efforts and press releases submitted regarding state 340B activity Current Legislative Session Activity in Washington

How Washington's Prescription Drug Affordability Board affects patient access: statute, board actions Washington PDAB Back to PDAB Policy Center Information, updates, and engagement opportunities related Public Comments Letters and testimony submitted regarding state PDAB activity CANN Public Comment: Washington PDAB Drug Selection Process Publication date: 7/10/25 Comment on Washington PDAB's drug selection process Other Healthcare Policy Areas in your state CANN monitors multiple healthcare policy initiatives across Washington

An opinion article by the Washington Post Editorial Board sheds more light on how the 340B program is How corporate welfare for hospitals is raising health care costs The Washington Post | By Editorial Board See The Washington Post’s full article HERE Public Comments Letters, testimony, and press releases submitted

NAWG's federal policy priorities, contribute to CANN's research, and convene on the issues moving in Washington Timely updates on what's moving in Washington and in state capitals — bills, regulatory action, executive

Ohio Illinois Michigan Oregon Iowa Minnesota Vermont Kansas Nevada Virginia Louisiana New Hampshire Washington spreadsheet behind CANN's ADA analysis — every PDAB-eligible drug across Colorado, Maryland, Oregon, and Washington July 23, 2024 Original data analysis of every PDAB-eligible drug in Colorado, Maryland, Oregon, and Washington

missing baseline data and need for non-UPL affordability solutions. 03/01/2026 CANN Public Comment: Washington sustainability and program integrity concerns at fiscal committee stage. 02/05/2026 CANN Public Comment: Washington patient experience while critics profit from the program. 02/11/2026 Press Release CANN Public Comment: Washington program integrity concerns at fiscal committee stage. 02/05/2026 Public Comment CANN Public Comment: Washington distribution assurances without addressing patient access. 01/27/2026 Public Comment CANN Public Comment: Washington

Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington, DC West Virginia Wisconsin Wyoming Top

Amanda Pratter Pronouns: she/her Role: Associate Director, Policy Advocacy, Gilead Sciences Location: Washington